AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01722604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azopt 1%
Description: Azopt 1%, RLD
Study NCT02184195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet -100mg
Study NCT02184195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet-150mg
Study NCT02184195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Match Olaparib 100mg placebo
Study NCT02184195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Match Olaparib 150mg placebo
Study NCT01707043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex
Description: Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
Study NCT01462435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Test (lower dose)
Description: Capsules
Study NCT01462435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Test (upper dose)
Description: Capsules
Study NCT01462435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 200 mg Capsules
Study NCT01462435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study NCT04689581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided bi-level erector spinae plane block
Description: Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
Study NCT04689581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided modified pectoral nerve block
Description: Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
Study NCT00803699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily placebo capsules for 12 months
Study NCT00803699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: selenium as L-selenomethionine
Description: daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
Study NCT00871182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT001
Description: single dose, inhaled
Study NCT00871182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: single dose, inhaled
Study NCT00871182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Handihaler
Description: single dose, tiotropium 18 mcg administered via the Handihaler
Study NCT02385149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole grain wheat
Description: A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
Study NCT02385149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: refined wheat
Description: A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
Study NCT00545298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide - same dose 6 wks
Description: 200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
Study NCT00545298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide modified treatment
Description: 200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
Study NCT01830751 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Restrained Sitting Treatment
Description: Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
Study NCT01830751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrained Sitting Treatment
Description: Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
Study NCT00333398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free
Description: CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
Study NCT00333398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Trivalent Inactivated Influenza Vaccine with Thimerosal
Description: CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
Study NCT00333398 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with Thimerosal
Description: Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
Study NCT04140656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plantar sensitive exercises
Description: Plantar sensitive exercises:~40 minutes / 3 days per week / 8 weeks Warm up exercise (5 minute) Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min) Cooling exercise (5 min)
Study NCT04140656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Textured insole
Description: Textured insole group.~Plantar sensitive exercises with insole 40 minutes / 3 days per week / 8 weeks (all exercises will be done with insoles) Warm up exercise (5 minute) Walking on flat ground (15 minute) Exercise with roller under the sole of the foot (5 minute) Seated work with barbed balance pad (5 min) Dorsi flexion and plantar flexion and hip flexion exercises (5min). Cooling exercise (5 min)
Study NCT03339206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constituent message with FDA and quitline
Description: Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
Study NCT03339206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constituent message without FDA and quitline
Description: Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
Study NCT03339206 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Littering message (Control)
Description: Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
Study NCT01087775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Plasticity Based Adaptive Cognitive Remediation (PACR)
Study NCT02668874 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Isolite System
Study NCT02668874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cotton Roll Technique
Study NCT01845922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Description: Low sodium diet
Study NCT03912142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: three dimensional Transperineal Ultrasound Scan
Description: Diagnostic test: three dimensional transperineal ultrasound scan
Study NCT00810004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Intravenous infusion of iron
Study NCT00810004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferinject
Description: Intravenous infusion of iron
Study NCT03542006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide Ophthalmic
Description: Topical brinzolamide given bd for 3 months
Study NCT03230552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructional surgical video
Description: An instructional surgical video shown to residents before they perform LSO surgery.
Study NCT00454259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl/Placebo injection
Description: Ultra low dose intravenous injection
Study NCT00454259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl/Placebo injection
Description: Ultra low dose intravenous injection
Study NCT04146740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Exercise for Experimental (Structured Exercise) Group
Description: Structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min.~The combination of Stabilization exercise (10 repeatitions) and PFM training ( 20 repeatitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repetitions) along with deep breathing exercises.
Study NCT04146740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control treatment for both groups
Description: Medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist.
Study NCT04146740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control treatment for both groups
Description: Medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist.
Study NCT00956397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: rifaximin 550 mg TID PO x 10 days
Study NCT00956397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
Study NCT00956397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo TID x 10 days
Study NCT04267419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: salivary biomarker
Description: MDA and NO as salivary biomarkers
Study NCT04346589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients
Description: Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria . Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.
Study NCT00891982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTGel/ BPO Wash
Description: Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days.
Study NCT00891982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soap Free Cleanser and CTGel
Description: Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days.
Study NCT04424654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: Testosterone cypionate 400 mg IM
Study NCT01617070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: Dosed at 20 mg/kg; PO; Phase 3, Phase 4
Study NCT01617070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Large Neutral Amino Acid Therapy
Description: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
Study NCT03707548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPT
Description: BPT will consist of 6 weekly group sessions, based on a scientific approach, integrating body-oriented techniques to improve patients' awareness, perception, acceptance, and expression regarding their body.
Study NCT03707548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-triggered bodily interventions
Description: Smartphone-triggered bodily interventions will consist of brief BPT exercises insuring the transfer from the group BPT sessions into patients' daily lives. Smartphone bodily interventions will be triggered by short audio-clips.
Study NCT03707548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone triggered control intervention
Description: The smartphone triggered control intervention will be selected fairy tales presented by audio-clips.
Study NCT02802540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.
Study NCT02802540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients going to take capsules of placebo until complete 8 weeks.
Study NCT02850926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer head gear
Description: Each head gear model consists of lightweight materials with a cross strap design that is fully adjustable or a single elastic headband. All models meet or exceed the American Society for Testing and Materials (ASTM) testing standards for soccer headgear and are approved by the National Federation of High Schools and The Fédération Internationale de Football Association (FIFA) for use by interscholastic soccer players. Players will be allowed to choose the brand of head gear to use and wear it for each practice and game during the soccer season.
Study NCT05462964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pacifiers Group (İntervention Group 1)
Description: Camera recording was started 2 minutes before OGT placement and only a pacifier was given to the newborn. After the pacifier in the OGT intervention group was placed in the mouth of the given baby in the form of leaking from the mouth, it was inserted by advancing the baby's swallowing reflex from the esophagus to the stomach. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.
Study NCT05462964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pacifier group sweetened with 25% dextrose (İntervention Group 2)
Description: Camera recording was started 2 minutes before OGT insertion and the newborn was given a pacifier sweetened with 25% dextrose. After the dextrose-sweetened pacifier in the OGT intervention group was placed in the mouth of the baby in the form of a leak from the mouth, it was inserted by advancing the baby's esophagus and then to the stomach with the swallowing reflex of the baby. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the registration was stopped.
Study NCT03231046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBCT-US Fusion Arm
Description: Use of Clear Guide SCENERGY for CBCT-US fusion guidance
Study NCT03231046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic Biopsy or Ablation
Description: Standard of Care
Study NCT01214928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: cholecalciferol 50,000 IU po once weekly for 12 weeks
Study NCT01214928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: cholecalciferol 50,000 IU po once weekly for 12 weeks
Study NCT00595322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bevacizumab and radiation (IMRT)
Description: bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains \< 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
Study NCT02777268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort
Description: Multi-particulate granules
Study NCT02777268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Tablet
Study NCT00839670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light constraint induced therapy
Description: 90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.
Study NCT00839670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard constraint induced therapy
Description: 360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
Study NCT03710174 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Infrared LED photobiomodulation
Description: Infrared LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of wavelength: 850 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2\~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later.
Study NCT03710174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Description: After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
Study NCT03710174 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LED photobiomodulation
Description: The same procedure as LED group with the device turned off.
Study NCT03715699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.
Study NCT03715699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone and Leflunomide
Description: Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months.
Study NCT04187638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
Study NCT04187638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
Study NCT04187638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Butter
Description: Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
Study NCT04187638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butter
Description: Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
Study NCT00524342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprelvekin, Interleukin 11, IL-11
Description: 25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
Study NCT01826110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PIB
Description: Approximately 15 mCI \[11C\]PIB IV x1